CNS Pharmaceuticals, Inc. CNSP
CNS Pharmaceuticals, Inc. (Nasdaq: CNSP) is an oncology drug developer. Its lead program, Berubicin (legacy, anthracycline; not under active development, available for out-license), is in Phase 2 for Recurrent glioblastoma / malignant glioma. Its next catalyst on record is Corporate: Acquire or in-license a new clinical-stage oncology or neurology asset (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Corporate — Acquire or in-license a new clinical-stage oncology or neurology asset (date not stated). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Berubicin | Recurrent glioblastoma (Orphan and Fast Track designations) | small molecule | Phase 2 |
| TPI 287 (abeotaxane; licensed from Cortice for US, Canada, Mexico, Japan) | Glioblastoma | small molecule | Phase 2 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.